Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs InMode Ltd (INMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs InMode Ltd — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while InMode Ltd trades at $14.9 (market cap $857.04M). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 9.4× InMode Ltd's market cap. Which is the better fit depends on your goals.
| BIO | INMD | |
|---|---|---|
Market Cap | $8.04B | $857.04M |
Sector | Health | Technology |
52-Week High | $339.75 | $16.62 |
52-Week Low | $241.71 | $12.76 |
Enterprise Value | $7.85B | $324.71M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
INMD trades at $15.15, down 0.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company maintains strong profitability with a 77.84% gross margin and a P/E of 11.04, indicating potential undervaluation. Recent news includes an unsolicited acquisition offer at $16.75 per share and upcoming Q2 2026 earnings on August 5, 2026, with revenue guidance of $95.2M-$95.4M.
The outlook is mixed: solid fundamentals and a takeover bid provide upside potential, but risks include earnings misses, legal investigations, and shareholder opposition to the acquisition. Analyst consensus is a $16.50 price target with a balanced buy/hold split, suggesting cautious optimism amid near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →
